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Introduction:
The side effects of therapy of hepatitis C virus
(HCV) infection have limited the number of
patients able to complete an effective course of
treatment and can dissuade patients and clinicians from embarking on such treatment. This is
true in the general population as well as the more
controlled correctional environment. Rates of
discontinuation of HCV therapy for laboratory
abnormalities or other clinical adverse events
range from 7 to 16% in both HCV treatment trials
and clinical practice.1,2
At the Hawaii Department of Public Safety, we
have implemented a successful HCV treatment
program for infected inmates. Although treatment
began for a few inmates as early as 1999, the
main emphasis on treatment started in late 2002.
Approximately 6,000 inmates reside in Hawaii's
prisons and jails, both of which are contained in
one system. Inmates reside in eight facilities on
four islands in Hawaii and in four private contract
facilities in four different mainland states. The
prevalence of HCV in our system in 1999-2001
was found to be approximately 30% when our
health department tested all inmates anonymously. Although testing for HIV is routinely offered to
inmates by our health department, screening for
HCV is conducted when an abnormal ALT is
detected or there is a history of injection drug
use, transfusions before 1992, known liver disease, HIV infection or hepatitis B virus (HBV)
infection. In addition, HCV testing is offered to
patients on hemodialysis and prior to treatment
with either isoniazid or statins, or on patient
request. After determining HCV seropositivity,
our current major criteria for consideration for
HCV treatment is an ALT greater than 1.5 times
normal (we previously used twice normal, but as
the literature suggests a small percent of persons
with progressive disease may have minimal or no
elevation of ALT, we reduced this level to 1.5
times normal). Viral load and genotyping are
then done to determine duration of treatment
required and the need for liver biopsy. At the current time, we only perform liver biopsies on HCV
genotypes 1 and 4. We do not treat fibrosis level
0 or 1, although we have made rare exceptions.
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Our guidelines currently require an expectation
for 12-18 months remaining in one's sentence,
but exceptions are made for those committed to
treatment and able to name an outside provider
who will continue treatment. We previously
required completion of or current participation in a
drug treatment program but we have dropped
that requirement for legal considerations. We do
require sobriety and conduct random urine drug
screens (after a signed agreement from the
patient).
In analyzing our clinical data, we noted that only
5% of 188 patients treated for HCV had discontinued HCV therapy for medical reasons and 2%
stopped treatment on their own for reasons that
may or may not have been related to side effects.
An additional 4% had their HCV therapy stopped
secondary to positive urine drug screens. No
patient has had a positive drug screen since
November 2002. All inmates are tested for HIV
prior to treatment; only three inmates of our treated population were co-infected.
While we suspect our approach to the management of treatment is similar to that of most
providers, our ability to recognize and respond to
HCV treatment-related toxicities is likely a significant factor contributing to the success we have
had in achieving treatment completion. In this
review we describe our approach to the management of the side effects we commonly encounter
during HCV therapy.
General approach to treatment
We aim to assign a nurse at each facility to take
responsibility for HCV management and also get
the active participation of the nurse administrator.
The overall management of HCV from diagnosis,
evaluation and consideration of liver biopsy,
explanation of the rationale for decisions not to
treat (e.g., liver biopsy with fibrosis 0-1), to supportive care during treatment, all require the
Continued on page 3
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EDITOR

Dear Corrections Colleagues,
At least 3 million people in the United States live with chronic Hepatitis C Virus (HCV) infection
and many are involved in the criminal justice system. In several areas of the country, the prevalence of HCV in prisons and jails exceeds 30% and in some prisons almost half of the inmates
are reportedly infected. The actual prevalence of HCV among inmates is certainly higher as
screening for HCV in correctional facilities is not universal.
The establishment of standards of care for HCV management, which include the use of expensive therapies, has led to an increased demand for HCV treatment among inmates but has
strained prison and jail health care budgets. While different facilities have adopted disparate and
individualized approaches to the financing of HCV therapy, the medical management of this infection in our correctional system should be much less variable. As detailed in IDCR (October, 2005,
July 2005), guidelines for the diagnosis and treatment of HCV have been established and include
recommendations made by the National Institutes of Health (NIH) and the American Association
for the Study of Liver Disease (AASLD) among others.
However, applying these recommendations to corrections has not always been straightforward
and among the arguments for the deferral of HCV therapy during incarceration the cost of treatment is often accompanied by concerns regarding its tolerability. In this issue, Drs. Bauman and
DeWitt from the Hawaii Department of Public Safety share their experience in managing the complications of HCV therapy and describe the underpinnings of their impressive rate of HCV treatment completion. Their success should be reassuring to correctional clinicians considering implementing HCV treatment programs. Their report is complemented by a series of insightful case discussions by Dr. Douglas Fish of the Albany Medical College. Later this year, Dr. David Paar will
report in IDCR on the evolution of the Texas Department of Corrections' policies on the diagnosis
and management of HCV.
The experience of these clinicians and those from other correctional systems make it increasingly difficult to reasonably justify the denial of HCV therapy to inmates who medically qualify for therapy and who will be incarcerated for a sufficient duration of time to receive treatment.
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(continued from page 1)

involvement of a consistent team of nurses
and other providers. Most clinical visits (frequently timed with lab draws) are with the
nurse on the treatment team. He or she
assesses whether or not additional physician
visits are also needed.
Patient expectations play a major role in the
subjective patient response to side effects.
During counseling, we stress the potential
benefits of the current treatment and use the
term "chemotherapy" to describe the treatment course itself. Some believe this is too
strong a term, but our experience supports
using this term, as it better predicts for the
patient the severity of the side effects. We
believe forewarned is fore-armed. We
explain the 60/40 "odds" of achieving a sustained viral response (SVR; non-detectable
virus at 6 months post treatment) or "cure"
for HIV-uninfected patients with genotype 1
HCV, but also the potential reduction in liver
inflammation and the resultant delay in the
complications from chronic HCV even in the
absence of SVR.3 This we describe to the
patient as "turning the clock back" on this disease.
Common side effects
Fatigue, headache, malaise, myalgias,
arthralgias This combination of symptoms
leads any list of HCV treatment side effects
and is reported to occur in over 50% of treated patients; in some studies this proportion is
as high as 72%.1-6 Most patients experience
these symptoms to some degree. Liberal
prescribing of analgesics may help with the
aches. Further, we administer pegylated
interferon injections on late afternoons on
Fridays so patients have the weekend to
recover. By Monday, they are usually able to
tackle work once again. Rarely have our
patients had to leave their work assignment
over the course of the treatment, although at
times some accommodations have had to be
made. In patients with preexisting chronic
pain, whether back, neck, shoulder or other,
this pain may worsen on treatment. Warning
the patient of this possibility prior to treatment can help the patient prepare for the
possible need for additional analgesics. We
rarely use narcotics in this situation. During
treatment, we are liberal with prescribing
what our system calls "medical rec", where
patients are allowed to get outside to walk
but are not be expected to participate in the
strenuous exercise such as basketball or
other games.

treatment; at small facilities mental health
screening is conducted by the primary care
physician. No specific depression inventory
is used. Exclusion from treatment on the
basis of psychiatric reasons, specifically
depression, is rare, but a patient with a history of depression with previous suicide
attempts may be ruled out for therapy. It is
also likely in our system that poorly-controlled psychotic patients do not get to the
evaluation-for-treatment stage. The pretreatment psychiatry visit does, however,
alert the mental health team that HCV therapy is being considered so that some patients
with pre-existing mental health problems
maybe followed more closely during their
HCV therapy. This pro-active approach has
resulted in no patients stopping treatment for
psychiatric side effects and there have been
no suicide attempts in patients during treatment. There have been unusual personality
changes in a small number of patients while
on treatment; nonetheless these inmates
were highly motivated to complete treatment
and were successful in achieving SVR.
During therapy anti-depressants, usually
selective serotonin reuptake inhibitors
(SSRIs), such as fluoxetin, are liberally prescribed. Although most psychotropic medicines in our facilities are prescribed by psychiatrists, patient management is conducted
by primary care physicians. In our system,
we do not use anti-depressants as prophylaxis for depression.
Nausea, anorexia, weight loss
The reported rates for nausea and/or anorexia range from 21 to 47%.1,2,6 As part of our
counseling, we inform patients that lighter
weight people seem to do better with HCV
treatment. Thus, the expected loss of
appetite and weight may actually help
achieve the desired long-term positive
response. Usually the gastrointestinal symptoms associated with HCV treatment occur in
the mornings, so by evening the patient is
able to eat. If a normal weight patient begins
losing weight we allow extra calories, usually
as an evening snack, for weight stabilization.
Patients with diabetes mellitus may need to
reduce or stop hypoglycemic medication during HCV treatment, even if significant weight
loss has not occurred. Costly nutritional supplement drinks are required only rarely.
Local skin reaction

Causes for fatigue developing during HCV
treatment is often detected by laboratory
evaluation. Conditions such as anemia, neutropenia, thrombocytopenia and thyroid
abnormalities can be detected early with
proper laboratory surveillance. Table 1 lists
our routine laboratory monitoring schedule.
The managing physicians review all laboratory tests.

A large number of our patients have a local
skin reaction to the weekly pegylated interferon injections; the literature gives a range
of 7 to 58% for this complication.2,6 With this
reaction, the injection site appears inflamed;
edges of the reaction are not well demarcated. Effectiveness of steroid cream varies. As
with other reactions, advising patients
beforehand prepares them. The skin condition lasts throughout interferon therapy, but
resolves over time upon completion.

Depression

Fever, chills, and rigor

Rates of depression during HCV treatment
range from 16 to 36%.1,2,6 At our largest
facility, patients are reviewed by the psychiatrist or other mental health worker prior to

Fever occurs in as many as 37 to 56% of
patients and 23 to 43% experience
chills/rigor.1,2,6 Usually, these complaints
can be managed with antipyretics. However,
three of our patients had severe rigors asso-

ciated with interferon injections. One male
patient elected to quit therapy because rigors
occurred with his first injection and he did not
want to suffer it again. A female experiencing a similar severe rigor tried a second injection (timed away from her insulin injection to
make sure a cross-reaction wasn't occurring), but after an almost shock-like reaction
recurred, therapy was discontinued. A third
patient had a similar reaction, but only after
several months of treatment. He continued
therapy and rigors did not occur with each
injection.
Hematologic complications
Anemia, defined as a hemoglobin < 11.0 g/dL
can occur in 19 to 36% of patients.1,6 It is
usually hemolytic in nature and related to the
ribavirin. We use the nationally recommended parameters and schedule for ribavirin
dose reduction for Hgb < 10.0 g/dL (Tables 2
and 3). Leukopenia, defined as WBC < 3.0 x
109/L, occurs in 17 to 45% of treated patients
and is more commonly related to interferon.1,6 Our current dose reduction parameters and schedule for WBC < 1.5 x 109/L or
absolute neutrophil count < 0.75 x 109/L are
noted in Tables 2 and 3. We have not needed to stop therapy in any of our patients due
to anemia or leukopenia.
Thrombocytopenia, defined as platelets <
100 x 109/L occurs in 4 to 11% of patients.1,6
Three of our patients had HCV therapy
stopped for severe thrombocytopenia, with
platelet counts < 50 x 109/L. Platelet transfusions are administered to patients with
compensated cirrhosis who begin therapy
with platelets < 100 x 109/L. Surprisingly
many of these patients are able to continue
treatment although the viral response rate is
lower than others with healthier livers. To
date, we have not used cellular growth factors, such as granulocyte colony stimulating
factor (GCSF), to avoid lowering doses of
either pegylated interferon or ribavirin, but
we have recently revised our HCV treatment
guidelines to add the use of erythropoietin to
help prevent ribavirin dose reduction due to
drug-induced anemia. The literature supports the importance of maintaining a full ribavirin dose early in treatment for best results.
The importance of the full dose of pegylated
interferon is not as clearly addressed in the
literature, so we have not included the use of
GCSF in our management. Although there
are limited data suggesting GCSF can
increase the number of WBCs in patients
receiving HCV therapy and can thus permit
higher interferon dosing, improvements in
SVR have not yet been demonstrated.7
A major challenge to treating HCV in corrections is economic: can we afford these
growth factors on top of the cost of HCV therapy itself? Our approach has been very conservative, but we added the erythropoeitin to
our formulary with the reasoning that this will
enhance success of an investment for treatment of $30,000 or more (for genotypes 1
and 4).

Continued on page 4
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Bacterial infections

One patient's HCV treatment was discontinued after three hospitalizations for cellulitis
while on therapy. The infection first began in
a tattoo acquired while on treatment. Our
pre-treatment counseling specifically forbids
the acquistion of new tattoos while on treatment, but on review of our consent form, it
did not include this statement. Since this
patient was insistent on continuing treatment
and denied knowing of this mandate, treatment was initially continued; two additional
episodes of infection ensued and treatment
was terminated due to recurrent severe
infections.
Severe jaundice
Although mild elevations of bilirubin are
reported in 11 to 28% of patients,6 severe
elevations of bilirubin, defined as bilirubin >
12.0 mg/dL have not been reported. Therapy
was discontinued in one or our patients experiencing severe jaundice with a bilirubin > 20
mg/dL while on treatment. His abdominal
ultrasound was negative. He recovered well
after stopping both medications and it was
not clear which drug was the cause of this
adverse event.
Decompensation of liver disease
One patient died after therapy had started.
His pre-treatment liver biopsy showed stage
3 fibrosis and not cirrhosis, thus making him
a candidate for treatment. Of note, his laboratory studies showed low platelets and a
normal albumin. These were consistent with
compensated cirrhosis, which did not show
in his biopsy, likely due to sampling variability. His pre-treatment physical exam did

show edema. A review of his care at a mortality conference after his death attributed his
worsening liver disease to underdiagnosing
cirrhosis, perhaps missed by biopsy. It is
known that the biopsy only reaches small
pieces of the liver and can underdiagnose
severity of disease. Interestingly, he was a
responder to treatment at both 12 and 24
weeks of care. Although his hemoglobin fell
at the beginning of treatment, it was not
below the threshold that triggers a change in
the ribavirin dose. A later drop in hemoglobin, after six months of treatment did prompt
a decrease in his ribavirin dose.
Investigation for other etiologies accounting
for the drop in hemoglobin such as gastrointestinal bleeding was not conducted. After
eight weeks of treatment, his WBC
decreased and required a reduction in the
interferon dose. After 24 weeks the patient's
WBC rose to 10.2 x 109/L but this was overlooked in terms of a search for an infectious
source. After eight and a half months of
treatment, he was hospitalized with an upper
gastrointestinal bleed. HCV treatment was
stopped, esophageal varices were diagnosed and portal hypertension was noted.
He developed methicillin resistant S.aureus
bacteremia secondary to an infected shoulder joint leading to acute renal failure and further hepatic failure. He continued to decompensate and expired of sepsis. This case
illustrates not only the seriousness of liver
dysfunction and the complexities of the management of such patients but also the limitations of HCV therapy in patients with more
advanced liver disease.
Summary

HCV therapy can complete their treatment
without serious adverse events. Some of our
success may be explained by our careful
selection of patients to receive HCV therapy;
however, our criteria for treatment are reasonable and inclusive. Further, few of our
patients were HIV-HCV co-infected and rates
of successful treatment completion in coinfected patients may differ from those we
observed.
We have learned that managing the side
effects of HCV therapy takes committed
providers and an educated nursing team. It
also requires pre-treatment education of the
patient and reassurance about the unpleasant effects these strong medications can
cause. Close and careful monitoring of laboratory parameters is necessary with orders
for medication dose changes if needed.
Awareness of the potential complications of
HCV therapy and the management of these
adverse effects is critical to maintaining therapy. Nonetheless, if these challenges are
addressed, sustained virologic responses in
patients on HCV treatment in corrections can
match or exceed the responses of programs
in our communities.

We would like to encourage are readers who receive IDCR via mail to
change your subscription to either fax
or email. Please fill out the subscription information below or change your
subscription online at
www.IDCRonline.org.

It has been our experience that the vast
majority of HCV-infected inmates receiving

Table 1. Laboratory Evaluations at Visit Week After Initiation of HCV Treatment (Genotype 1)
During HCV Therapy

Lab Evalutation
CBC/Diff/PLTS
AST/ALT
Bilirubin Direct
PT/PTT
AFP
ANA
TSH
Uric acid
Triglycerides (fasting)
HCV (quantitative)

2
X

4
X
X

6
X

8 12 16 20 24 28 32 40 44
X X X X X X X X X
X X
X X X X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

Post HCV Therapy
48
X

4
X
X

X
X
X
X
X
X
X
X

8
X
X

12
X
X

24
X
X
X
X
X
X
X
X
X
X

Table 2. Parameters for Dose Reduction
Parameter
Hemoglobin
White Blood Cell
Neutrophil Count
Platelet Count
Bilirubin Direct
Bilibrubin Indirect
Creatinine
ALT / AST

Dose Reduction
< 10 g/dL (Ribavirin)*
< 1.5 x 109/L (Interferon)*
< 0.75 x 109/L (Interferon)*
< 80 x x 109/L (Interferon)*
> 5 mg/dL (Ribavirin)*

Permanent Discontinuation of Treatment
(Both pegylated interferon and ribavirin)
< 8.5 g/dL
< 1.0 x 109/L
< 0.5 x 109/L
< 50 x 109/L
> 2.5 x upper limit of normal
> 4.5 mg/dL (for >4 weeks)
> 2.0 mg/dL
> 2 x baseline AND > 19 x upper limit of normal
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Table 3. Dose Reduction
MEDICATION
INITIAL DOSE
Pegylated Interferon
Pegasys
Peg-Intron
Ribavirin

180 mcg SC/wk
1.5 mcg/kg SC/wk
800 mg QD
1000mg QD(<75kg)
1200mg QD(>75kg)

TOTAL NO. OF
CAPSULES/DOSES

NA
2 capsules am/
2 capsules pm
3 capsules am/
2 capsules pm
3 capsules am
3 capsules pm

REDUCED DOSE

135 mcg SC/wk
0.75mcg/kg SC/wk
600 mg QD
(dec. 200 at a time)
800mg QD
(dec. 200 at a time)
1000 mg QD
(dec. 200 mg at a time)

TOTAL NO. OF
CAPSULES/DOSES

NA
1 capsule am/
2 capsules pm
2 capsules am/
2 capsules pm
2 capsule am/
3 capsules pm
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Case 1: Does this patient need HCV
therapy?
A 45 year-old male inmate is diagnosed with
HCV infection after he is found to have an
elevated AST and ALT of 69 and 75 IU/L,
respectively, on routine admission screening. His bilirubin is normal, and his albumin
is 4.2 gm/dL. He feels well. He reports that
he injected heroin for several years in his
early twenties.
Question: How do we know whether or not
this patient needs treatment for HCV?
Discussion
The first thing we should do is determine
whether or not he has chronic HCV infection
as 15-25% of people who are exposed and
infected with HCV will clear the virus on their
own. This is in contrast to hepatitis B virus
(HBV) infection, where 90-95% of people
will spontaneously clear hepatitis B DNA if
infected as an adult. Chronic HCV infection
is determined by ordering a viral load for
HCV, known as an HCV RNA PCR. Given
the patient's elevated transaminases and
his history of injection drug use (IDU), his
pre-test probability of having chronic HCV
infection is high.
His viral load returns at 600,000 IU/mL, con-

firming chronic infection. If the viral load
result is undetectable, the test should be
repeated in 3-6 months for verification, and
the patient would be confirmed as NOT having chronic infection, with no treatment necessary.
The next step in evaluation of a patient with
HCV viremia - in addition to screening for
other forms of hepatitis, including hepatitis A
virus (HAV) infection, HBV infection, autoimmune liver disease, and HIV - would be an
assessment of the genotype, or strain of
HCV, and consideration of liver biopsy. It is
important to remember that HCV-infected
patients can have significant fibrosis and
even cirrhosis, yet have normal transaminases (AST and ALT). The genotype helps
determine the length of HCV therapy and
the likelihood of treatment response.
Patients with genotypes 2 or 3 are usually
treated for 24 weeks, whereas patients with
genotypes 1 or 4 are treated for 48 weeks.
Most hepatitis specialists recommend a liver
biopsy, though there are situations where a
biopsy may not be needed, particularly if
one plans to treat regardless of a biopsy
result. Patients with genotypes 2 or 3 have
such a favorable treatment response that
the 2004 American Association for the Study
of Liver Disease (AASLD) treatment guidelines state that a liver biopsy in such patients
can be considered optional. A liver biopsy
does carry bleeding risks and a small risk of
death (1/10,000 deaths).
Treatment responses are poorer in patients
with genotype 1. A liver biopsy can help
determine how much scarring, or fibrosis,
there is in the patient's liver and this information can be useful to the patient and clinician before and during HCV therapy. There
are different scoring systems pathologists
used for measuring liver fibrosis, and a com-

mon one is the Metavir fibrosis score (see
HCV 101). The score ranges from F0 to F4,
with F0 meaning no fibrosis and F4 signifying cirrhosis. If there is no fibrosis (Metavir
F0), the patient does not need treatment
and can be followed with a repeat biopsy in
3 to 5 years to look for progression. This is
true regardless of the amount of inflammation seen in the biopsy (Metavir "A" score).

Opportunities to support
IDCR are available!
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Sponsor for 2007
Fully CME accredited and
peer-reviewed.
Contact Elizabeth Closson, IDCR
Managing Editor at (401)453-2068 or
idcrme@gmail.com.
If on liver biopsy, the patient has a Metavir
score of F1, some experts would recommend treatment and others would observe,
with a repeat biopsy in three to five years.
The 2002 National Institutes of Health (NIH)
Consensus Panel on HCV recommended
treatment for patients with Metavir scores of
F1 or higher. Similar to the AASLD guidelines, if the patient's virus is genotypes 2 or
3, this panel felt that a liver biopsy would be
optional and hence not critical to the evaluation. HCV genotypes 2 and 3 respond
more favorablly than genotypes 1 and 4 and
usually require a shorter course of treatment, unless HIV-co-infection is present.
HIV-HCV co-infected patients have a higher
relapse rate when treated for 24 weeks, so
most experts recommend 48 weeks of treatment regardless of genotype for these
patients.
Continued on page 6
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Liver biopsy results may also be helpful to
patients during therapy. If adverse effects of
HCV therapy emerge and threaten treatment discontinuation, patients with more
severe pathology may feel motivated to preserve whereas those with relatively milder
disease on biopsy can consider this when
weighing the risks and benefits of continuing
treatment.
If the patient has a coagulopathy, such as
prolonged prothrombin time (PT) or thrombocytopenia, a biopsy can by done by an
interventional radiologist via the transjugular
approach. In cases where the patient
declines a biopsy due to fear of the test or
other concerns, treatment should not be
withheld, regardless of genotype.
Some laboratories offer a panel of blood
tests used as non-invasive markers of fibrosis, which might be helpful for patients who
decline or can't receive a biopsy. These
tests, however, are not as helpful as a biopsy. Some data also suggest that the ratio of
the platelet count and serum albumin can be
used to gauge liver fibrosis.
It is important to remember if the patient is
not immune to HAV or HBV, vaccination for
these should be offered so the patient does
not acquire infection with another hepatitiscausing virus on top of the one he or she
already has. Screening for treatment should
also include assessing thyroid function, cardiac status, mental health, and overall medical history. A past history of depression or
other mental illness should not necessarily
preclude treatment; more important is an
assessment of the patient's current mental
health.
The history and physical exam can also give
important information. Historical elements
that are important include the length of time
since a patient first injected drugs, and alcohol consumption. Most patients are infected
with hepatitis C early on, often in their first
year of injection drug use. Alcohol is a clear
risk factor for progression of fibrosis, and
patients should be advised to avoid all alcohol on release. The physical exam can
reveals stigmata of cirrhosis, such as palmar
erythema, spider angiomas, splenomegaly,
and asterixis. Laboratory clues to cirrhosis
include thrombocytopenia, low albumin,
hyperbilirubinemia, and prolonged prothrombin time.
To summarize, if the patient has detectable
viremia with HCV, obtain a genotype. If the
genotype is 1 or 4, a biopsy is generally recommended, though not required, for treatment. If the patient has genotype 2 or 3, a
biopsy is less critical as treatment duration
is shorter and treatment responses are higher - advantages that favor treatment regardless of biopsy result. If on liver biopsy, the
patient has more than portal fibrosis
(Metavir F2 or higher) and does not have
decompensated liver disease, treatment is
indicated. The standard treatment is now
pegylated interferon with ribavirin. Patients
with genotype 1 or 4 are assessed after 12
weeks of combination therapy, and if they
have a treatment response, designated as
at least a 2-log10 decrease or an undetectable viral load, treatment should be continued for 36 more weeks, or 48 weeks total.
For patients with genotypes 2 or 3, 24

weeks of combination therapy is recommended. A sustained virologic response
(SVR) is determined when the patient's viral
load remains undetectable 24 weeks after
therapy is completed.
In this patient, a liver biopsy was performed
and revealed a Metavir score of F2. He was
found to be HIV-uninfected and susceptible
to HAV. His HBV surface antibody and core
antibody were both positive, indicating prior
and resolved infection with that virus. His
HCV genotype was 1 and he elected to start
HCV therapy with ribavirin and interferon.
Case 2: HCV therapy in a patient with
cirrhosis
A 48 year-old woman with chronic HCV
infection undergoes a liver biopsy and is
found to have cirrhosis with a Metavir score
of F4. She has been incarcerated for two
years, and started injecting drugs when she
was 19 years old.
Question: Given that she has cirrhosis, can
she be treated for her HCV?
Discussion
Cirrhosis can be broadly broken down into
two categories, compensated and decompensated. Decompensated liver disease
implies hepatic encephalopathy, uncontrolled ascites, bleeding varices, or any of
the late-stage consequences of cirrhosis.
Determination of the patient's Childs-Pugh
Score is useful to determine whether a
patient's cirrhosis is decompensated. (see
HCV 101) Each element is scored and the
points calculated, with the maximum being
15, the worst score. Child's class A is compensated (score 5 or 6), Child's Class B is
early decompensated (score 7-9), and
Child's Class C is decompensated (score of
10 or higher) cirrhosis. Decompensated cirrhosis can be worsened by treatment with
interferon and ribavirin. Patients with compensated cirrhosis should only be treated
with the input of a clinician experienced in
the management of patients with HCV.
Patients with compensated cirrhosis may be
treated with interferon and ribavirin, though
they will require closer follow-up and more
frequent laboratory monitoring to avoid untoward complications of therapy. Again, therapy should be undertaken only in conjunction with a clinician experienced in the management of such patients. Consideration for
transplant listing should also be undertaken,
if appropriate. Sustained virologic response
rates are lower in patients with cirrhosis than
in patients without cirrhosis. Patients with
compensated cirrhosis typically have had
stable liver disease for years and usually do
not present often to sick-call or require hospitalization. As mentioned above, it is
important to recognize that a subset of HCVinfected patients may have cirrhosis demonstrated by liver biopsy, yet have normal liver
parameters, including normal transaminases and albumin. This is another reason
many experts recommend a liver biopsy for
patients with chronic HCV infection.
This patient has cirrhosis but no evidence of
decompensated disease and. As such, she
is a candidate for HCV therapy.

Case 3: Managing advanced liver
disease
A 55 year-old male with chronic HCV infection returns to your facility after being hospitalized for fever, ascites and a 25-pound
weight gain over the preceding two months.
He is on spironolactone 50 mg po bid and

Go to www.AAHIVM.org to learn about membership, continuing education and the new
partnership with IDCR

furosemide 40 mg po daily. He was treated
for spontaneous bacterial peritonitis, and is
now off antibiotics. He had an episode of
confusion while hospitalized, and was found
to have an ammonia level elevated at 50
Umol/L. He is now on lactulose 30 mL (20
gm) po bid. An upper endoscopy revealed
moderate esophageal varices, and he was
started on nadolol 20 mg po daily. He also
has type 2 diabetes mellitus treated with an
oral hypoglycemic, as well as chronic neuropathy pain, for which he had been on
ibuprofen but for which he is now prescribed
oxycodone.
Question: How should this patient be managed, and what signs/symptoms should you
expect?
Discussion
This patient will most likely come to your
infirmary initially. His fluid balance may not
yet be fully stabilized, so he will need monitoring of his weight several times per week,
as well as close follow-up of his electrolytes.
Adjustments may still need to be made in his
diuretic therapy. A low-salt diet is best, and
the patient may have been discharged on
fluid restrictions. This patient has decompensated liver disease, and hence, is not a
candidate for interferon/ribavirin therapy.
In this type of patient, chronic acetaminophen therapy is contraindicated, as it
may accumulate in his liver and cause additional problems. Furthermore, many such
patients typically have thrombocytopenia
and prolonged prothrombin times, increasing their bleeding risk. For patients with
esophageal or gastric varices, aspirin and
non-steroidal anti-inflammatory medications
are also relatively contraindicated, so as to
avoid bleeding complications. In addition,
concomitant gastritis or duodenitis is common, and patients may require an H2-blocker or proton-pump inhibitor therapy.
Oxycodone or low-dose morphine preparations, either short- or long-acting, may be
appropriate analgesics to control chronic
pain. Finally, these patients are at risk for
renal failure (hepatorenal syndrome) and as
they are often on diuretic therapy nonsteroidal medications pose further risk.
Hepatic encephalopathy is often managed
with lactulose. The goal is to titrate the lactulose to soft/loose stools without severe
diarrhea to help eliminate hepatic by-products. The level of serum ammonia elevation
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does not correlate well with the degree of
encephalopathy. Once a patient has been
diagnosed with hepatic encephalopathy,
clinical monitoring will be more useful than
following ammonia levels. Medications that
depress central nervous system function,
such as benzodiazepines, should be avoided as much as possible. Other medications
that may be prescribed in patients to reduce
the effects of hepatic encephalopathy
include antibiotics such as neomycin,
metronidazole, or rifaximin - a nonabsorbable derivative of rifampin.
Patients with varices will often be prescribed
a beta-blocker, as in this case, in an attempt
to decrease portal pressure and reduce
bleeding risks. Some clinicians may also
recommend antibiotic prophylaxis for

patients with ascites to prevent spontaneous
bacterial peritonitis, particularly if the patient
has had a previous episode of peritonitis.
Antibiotic prophylaxis has not been shown
to confer a survival advantage, however.
This type of patient should be considered for
orthotopic transplantation evaluation, if
available. His clinicians must discuss with
the patient the severity and life-threatening
nature of his illness, as well as health care
proxy and resuscitation wishes.
Life
expectancy will be greatly reduced and may
be measured in months to years.
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HCV101
Child-Pugh Classification
Modified Child-Pugh classification of severity of liver disease according to the degree of
bilirubin, albumin, the prothrombin time, ascites, and encephalopathy.
Measure
Bilirubin mg/dL
Albumin g/dL
Prothrombin Time
Seconds Over Control
INR
Ascites
Hepatic encephalopathy
Grade
A: well-compensated disease
B: significant functional compromise
C: descompensated disease

1 point
<2
>3.5

2 points
2.0 - 3.0
2.8-3.5

3 points
>3
<2.8

1.0-3.0
<1.8
None
None

4.0-6.0
1.8-2.3
Slight
Grade 1-2

>6
>2.3
Moderate
Grade 3-4

Points
5.0-6.0
7.0-9.0
10.0-15.0

1 yr patient survival %
100
80
45

2 yr patient survival %
85
60
35

Metavir Scoring System
Stage
0
1
2
3
4

Amount of Scarring
No Scarring
Minimal Scarring
Scarring has occurred and extends beyond the areas of the liver that contain blood vessels
Bridging Fibrosis is spreading and conecting to other areas that contain fibrosis
Cirrhosis or advanced scarring of the liver
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NEWS AND LITERATURE REVIEWS
Factors Associated with Seronegative Chronic
Hepatitis C Virus (HCV) Infection in HIV Infection
HIV-infected individuals may not mount typical serologic responses to infections including HCV. This
group of investigators sets out to determine the
prevalence of chronic seronegative HCV infection in
a large, multi-center, nationally representative cohort
of HIV-infected men and women (The FRAM Cohort).
Their results, published in Clinical Infectious
Diseases, demonstrate that among the 1,174 antiHCV-negative study particpants, the prevalence of
seronegative HCV infection as determined by HCV
RNA testing was 3.2%. Notably, by multivariate logistic regression analysis, the researchers were able to
determine factors associated with HCV RNA positivity in anti-HCV-negative subjects. These factors were
history of injection drug use (IDU), higher alanine
aminotransferase (ALT) levels, and CD4+ cell counts
<200 cells/l. Among those HIV-infected individuals
with a history of IDU and either an abnormal ALT level
or CD4+ cell count <200 cells/l, the prevalence of
seronegative HCV infection was 24%. The authors
suggest that the low overall prevalence of seronegative HCV infection, while still greater than reported
prevalence in HIV-uninfected patients, demonstrates
that the HCV EIA 2.0 assay, commonly used in many
institutions, is a sufficiently sensitive screening tool to
determine antibody status. However, the findings
suggest that HCV RNA testing should be performed
in anti-HCV-negative HIV-infected patients, especially those with a history of IDU and either a CD4+ cell
count <200 cells/l or an abnormal ALT level.
Factors Associated with Seronegative Chronic
Hepatitis C Virus Infection in HIV Infection. Chamie,
G et al. Clinical Infectious Diseases 2007;44:577583.
Estimating the Future Health Burden of Chronic
Hepatitis C and Human Immunodeficiency Virus
Infection in the United States
Using two back calculation models, Deuffic-Burban et
al. estimated the future disease burden of HCV and
HIV infections in the United States. The study, the
first of its kind to account for antiviral treatment
advances, utilized United States epidemiological data
from the Centers for Disease Control and Prevention
(CDC) and the World Health Organization (WHO).
Based on past incidence, it appears that the HCV
incidence in the peaked in 1984 at 350,000 new
infections then fell to 77,000 in 1998, while HIV incidence reached a maximum in 1989 at 142,000 new
infections before declining to 79,000 in 1998.
Looking forward, the investigators estimate that mortality related to HCV, defined as death from liver failure or hepatocellular carcinoma, will peak at nearly
13,000 in the 2030, having risen from only 3,700 in
1998. The authors assert that predicted HCV mortality will fall only if there is increased access to treatment or more effective antiviral development. In
comparison, HIV-related mortality will drop to approximately 4,200 in 2030, down from 14,400 in 1998.
These results showcase the decline in HIV-related
mortality due to the effectiveness of HAART, but highlight the growing burden HCV-related death over the
next twenty-five years.
Estimating the Future Health Burden of Chronic
Hepatitis C and Human Immunodeficiency Virus
Infection in the United States. Deuffic-Burban et al.
Journal of Viral Hepatitis 2007;14:107-115.
Do Condoms Cause Rape and Mayhem? The
Long-Term Effects of Condoms in New South
Wales' Prisons
Researchers from Australia, seeking to address the
concerns of politicians, prison staff, and inmates,
examined the long-term effects of the introduction of

condoms and dental dams into New South Wales'
prisons. Their findings, published in Sexually
Transmitted Infections, demonstrate that most of the
concerns regarding condoms in prisons were not
realized. In contrast to the general expectations, the
investigators reported an overall decrease in both
self-reported consensual male-to-male sex as well as
male sexual assaults over the five year period condoms became available to inmates. While there were
reported incidents of prisoners using condoms to
conceal contraband material, such as tobacco, there
was no associated increase in IDU. Additionally, the
fear that condoms would be used as weapons was
not born out, as there were only three reported incidents of condoms being used in assaults; none of
which were serious. The data were derived from
Inmate Health Surveys of randomly selected prisoners from all prisons and official New South Wales
Department of Corrective Services' reports taken at
the beginning of the distribution program in 1996 and
then again in 2001. The authors note that the
decrease in both consensual sex and sexual assault
among male prisoners may be due to other factors,
including the introduction of an HIV/AIDS education
program in 1996. However, they suggest that the
presence of condoms in the prisons may have further
raised awareness and reinforced the prevention messages. The investigators conclude that the introduction of condoms did not cause the mayhem that many
had feared and note that opposition to the distribution
program soon dissipated.
Do Condoms Cause Rape and Mayhem? The LongTerm Effects of Condoms in New South Wales'
Prisons. Yap, L et al. Sexually Transmitted Infections
published online 19 Dec 2006.
Reduction in Triglyceride Level With N-3
Polyunsaturated Fatty Acids in HIV-Infected
Patients Taking Potent Antiretroviral Therapy
Hypertriglyceridemia is the hallmark dyslipidemia
associated with HIV infection. N-3 polyunsaturated
fatty acids (PUFAs), such as fish oil, have been found
to reduce triglyceride levels in HIV un-infected
patients. This double blind, randomized study
assessed the evolution of triglyceride levels in HIVinfected patients receiving stable HAART treated with
fish oil. One hundred and twenty-two patients with
baseline triglyceride levels between 200-1000 mg/dL
were randomized for eight weeks to fish oil (2 g of fish
oil three times daily) or placebo. At week eight, the
median change in triglyceride levels was -25.5% in
the fish oil group versus 1% in the placebo group.
Triglyceride levels were normalized in 22.4% of the
fish oil group, as opposed to only 6.5% of the placebo group. An eight week open label phase, during
which all patients received fish oil supplementation,
followed the initial eight week randomized period.
The decrease in triglyceride levels was sustained in
the original group assigned fish oil at week 16,
whereas a 21.2% decrease occurred for patients in
the placebo group who were switched to active drug
at week 8. Significantly, the incidence of adverse
events during the randomized double blind study
period was not more frequent in the fish oil group;
minor gastrointestinal disorders without vomiting
being most common. Additionally, CD4+, CD8+ and
viral load measurements were stable throughout the
study. The authors suggest these results, which are
comparable to previous randomized, open-label studies, demonstrate the efficacy and safety of fish oil to
reduce some of the risk associated with hypertriglyceridemia in HIV-infected patients on HAART.
Reduction in Triglyceride Level With N-3
Polyunsaturated Fatty Acids in HIV-Infected Patients
Taking Potent Antiretroviral Therapy. Truchis, P et al.
J AIDS. 2007.
Complied by Ross Boyce
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CONTINUING MEDICAL EDUCATION CREDIT

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing
Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and IDCR. MEC is accredited by the ACCME to
provide continuing medical education for physicians.
Medical Education Collaborative designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only
claim credit commensurate with the extent of their participation in the activity. Statements of credit will be mailed within 6 to 8 weeks following the
program.
Objectives:
The learner will be able to describe the common side effects of hepatitis-C therapy.
The learner will be able to identify the parameters for discontinuation of hepatitis-C therapy.
The learner will be able to identify commonly prescribed medications for various side effects of hepatitis-C therapy.

4.

1.

Which of the following is NOT a common side-effect of hepatitis C
therapy:
A. Fatigue
B. Chronic diarrhea
C. Headache
D. Malaise
E. Arthralgias

2.

Which of the following parameters requires the permanent discontin
uation of treatment for patients receiving hepatitis C therapy:
A. White blood cell count of < 1.0 x 109/L
B. Bilirubin Direct of >2.5 x upper limit of normal
C. Hemoglobin of <8.5 g/dL
D. ALT >1.5 mg/dL

3.

Detection of decompensated cirrhosis in a patient with HCV infec
tion is an indication for ribavirin and interferon.

Lactulose, neomycin, metronidazole, and rifaximin, are all medica
tion’s that can be used for which of the following:
A. Hepatic encephalopathy
B. Thrombocytopenia
C. esophageal varices
D. All the above

5. According the results reported by Chamie, G et al., seronegative
HCV infection in patients with HIV is more likely in all the following
situations EXCEPT:
A. CD4+ cell count less than 200/uL
B. History of injection drug use
C. Hepatitis B virus co-infection
D. None of the above

TRUE or FALSE?

In order to receive credit, participants must score at least a 70% on the post test and submit it along with the credit
application and evaluation form to the address/fax number indicated. Statements of credit will be mailed within 6-8 weeks
following the program.
Instructions:

• Applications for Credit will be accepted until
February 28, 2008.

• Late applications will not be accepted.
• Please anticipate 6-8 weeks to recieve your certificate.
Please print clearly as illegible applications will result in a delay.

Name:

_________________________________________________ Profession: __________________________________

License #: ___________________________________ State of License: __________________________________________
Address: ____________________________________________________________________________________________
City: ________________________ State: ________ Zip: ________________________ Telephone: ___________________
Please Check which credit you are requesting

___ ACCME or

___ Non Physicians

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------I certify that I participated in IDCR monograph - February 2007 Issue
Please fill in the number of actual hours that you attended this activity.
Date of participation: ______________________
Number of Hours (max. 1): ___________________
Signature: _________________________________________________

Please Submit Completed Application to:
Medical Education Collaborative
651 Corporate Circle, Suite 104, Golden CO 80401
Phone: 303-420-3252 FAX: 303-420-3259
For questions regarding the accreditation of this activity, please call
303-420-3252

February 2007

Vol. 9, Issue 13

10

visit IDCR online at www.IDCRonline.org

COURSE EVALUATION
I. Please evaluate this educational activity by checking the appropriate box:
Activity Evaluation

Excellent

Very Good

Good

Fair

Faculty
Content
How well did this activity avoid commercial bias and present content that
was fair and balanced?
What is the likelihood you will
change the way you practice based
on what you learned in this activity?
Overall, how would you rate
this activity?

II. Course Objectives
Were the following overall course objectives met? At the conclusion of this presentation, are you able to:

•
•
•

The learner will be able to describe the common side effects of hepatitis-C therapy.
The learner will be able to identify the parameters for discontinuation of hepatitis-C therapy.
The learner will be able to identify commonly prescribed medications for various side effects
of hepatitis-C therapy.

III. Additional Questions
a. Suggested topics and/or speakers you would like for future activities.

b. Additional Comments

YES
YES
YES

NO
NO
NO

SOMEWHAT
SOMEWHAT
SOMEWHAT

Poor

